Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here. During a presentation at ...

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

Highlighting the event is the immersive simulation, “Seeing Beyond the Ordinary and Repairing Damages,” led by world-renowned ...

Ozempic has made headlines as a go-to medication for managing diabetes and aiding weight loss, but its popularity comes with ...

The collaboration will focus on preventive solutions, workshops, and public awareness. King Faisal Specialist Hospital and ...

This code is designed for detecting Diabetic Retinopathy in retinal fundus images using a deep learning approach. It preprocesses the images, applies data augmentation to improve model generalization, ...

Ocugen, Inc. (NASDAQ: OCGN) this week announced the dosing of the first patient in its Phase 1 clinical trial for OCU200, a ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Retinal Biologics Industry. The retinal biologics market experienced significant growth in 2021, with total revenue reaching ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

For those who struggle with insurance or can’t afford cutting-edge health care, there’s an eye-opening opportunity coming to ...

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...